{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[18,2,18,3],[19,2,19,3],[21,2,21,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910908379503321"]
[null,null,"Autore",null,"Nandave Mukesh"]
[null,null,"Titolo",null,"Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure : Mechanisms and Clinical Applications: A Machine-Generated Literature Overview / / edited by Mukesh Nandave"]
[null,null,"Pubbl/distr/stampa",null,"Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024"]
[null,null,"ISBN",null,"9789819775682"]
[{"$nulls":4},"9789819775675"]
[null,null,"Edizione",null,"[1st ed. 2024.]"]
[null,null,"Descrizione fisica",null,"1 online resource (536 pages)"]
[null,null,"Disciplina",null,"615"]
[null,null,"Soggetti",null,"Pharmacology"]
[{"$nulls":4},"Medicine - Research"]
[{"$nulls":4},"Biology - Research"]
[{"$nulls":4},"Pharmacovigilance"]
[{"$nulls":4},"Medicine"]
[{"$nulls":4},"Cardiology"]
[{"$nulls":4},"Biomedical Research"]
[{"$nulls":4},"Drug Safety and Pharmacovigilance"]
[{"$nulls":4},"Clinical Medicine"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Chapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry -- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes  -- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes -- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction -- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy -- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure -- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose "]
[{"$nulls":4},"Cotransporter-2 (SGLT2) inhibitors -- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes -- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor’s effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes."]
[null,null,null,"Sommario/riassunto","The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage."]